Email Contact Phone Company Visit Website

Location Office

Kungsgatan 36
Stockholm
SE

NASDAQ OMX New York Head Office

One Liberty Plaza
New York
NY
US

NASDAQ OMX Stockholm Office

Tullvaktsvägen 15
Stockholm
SE

NASDAQ OMX Rockville Office

805 King Farm Boulevard 1st and 2nd floor
Rockville
MD
US

NASDAQ OMX London Office

Woolgate Exchange, 25 Basinghall Street, City of London
London
GB

NASDAQ OMX New York Office

Marketsite 4 Times Square
New York
NY
US

NASDAQ OMX Hong Kong Office

Room 1207-8, 12/F Man Yee Building 68 Des Voeux Road Central Hong Kong
Hong Kong
HK

NASDAQ OMX Singapore Office

20 Collyer Quay, #17-01
Singapore
SG

NASDAQ OMX Chicago Office

One North Wacker Drive Suite 3600
Chicago
IL
US

NASDAQ OMX Belgium Office

Avenue de Cortenbergh 116
Brussels
BE

NASDAQ OMX Dubai Office

Dubai World Trade Centre Sheikh Zayed Road
Dubai
AE

NASDAQ OMX Tokyo Office

1F, Kojimachi Square Building Nibancho, 3 Chiyoda-ku, Tokyo
Tokyo
JP

NASDAQ OMX Boston Office

100 Franklin St
Boston
MA
US

Location Office

Level 17-19, 110 Bishopsgate
London
GB

Telephone

212 231 5018

Contact

Todd A Swearingen
[email protected]
Back to all NASDAQ OMX announcements

NASDAQ OMX Welcomes Immunicum AB to First North

NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in Immunicum AB (short name: IMMU) shares will commence today on First North at NASDAQ OMX Stockholm. Immunicum belongs to the Healthcare sector and is the fifth new company to be admitted to trading on First North in 2013.

Immunicum develops cancer immunotherapies. The company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX™, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be produced in large scale.

“This is an exciting day for Immunicum and we welcome the nearly 900 new shareholders that participated in the IPO,” said Jamal El-Mosleh, CEO at Immunicum. “At First North we aim to gain increased exposure for our unique products by reaching out to a wider investor audience. Now we look forward to leveraging our publicly traded status in order to build our brand and support continued financial growth to our shareholders.”

“We congratulate Immunicum on their oversubscribed IPO and welcome them to First North and our healthcare sector,” said Emelie Jarnesten, head of NASDAQ OMX First North. “First North continues to be successful in attracting entrepreneurial growth companies and we welcome more companies to take advantage of the investor visibility and reach that we can offer.”

Immunicum has appointed G&W Fondkommission as Certified Adviser.